Product Development
OX40L pipeline: Data Byte
Jan 12, 2021 | 3:21 AM GMT
Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program
Gathering data...
Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program